# Regeneron Pharmaceuticals Inc. (REGN) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $827.72, market value $85.2 billion.

## Valuation
- **P/E (trailing): 20.5×** (5-yr avg 17.9×, 3-yr avg 20.7×). Regeneron Pharmaceuticals Inc. trades at 20.5× trailing earnings, close to its own five-year average of 17.9×. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 13.7×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 1.67**. A PEG of 1.67 is in the range usually read as fairly priced for its growth.
- **Price / sales: 5.5×**. Each dollar of revenue is priced at 5.5×.
- **Price / book: 2.6×**. The shares trade at 2.6× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 19.2×**. Enterprise value is 19.2× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 4.4%** (5-yr avg 5.6%). Free cash flow equals 4.4% of the market value, below its five-year average of 5.6%, so the shares are pricier on cash than usual.
- **Earnings yield: 4.9%**. The inverse of the P/E: 4.9% of the price is earned each year.

## Profitability
- **Operating margin: 24.7%**. 24.7% of revenue is left after running the business, a healthy level in most sectors.
- **Net margin: 31.4%**. 31.4% of each dollar of sales reaches the bottom line.
- **Return on equity: 14.4%**. 14.4% on shareholders' equity is solid.
- **Return on invested capital: 10.1%**. Return on all capital, debt included, is 10.1%.
- **Return on assets: 10.7%**. Each dollar of assets produces 10.7% of profit.

## Growth
- **Revenue growth (1 yr): 1.0%** (3-yr 5.6%/yr, 5-yr 11.0%/yr). Revenue grew 1.0% over the last year, against 11.0% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 8.2%** (3-yr 2.8%/yr, 5-yr 6.3%/yr). Earnings per share rose 8.2%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): -2.7%/yr**. Free cash flow has compounded at -2.7% a year over three years, lagging earnings: check whether profits are turning into cash.

## Financial health
- **Debt to equity: 0.06**. Debt is 0.06 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. Regeneron Pharmaceuticals Inc. holds more cash than debt.
- **Altman Z-score: 7.22**. A Z-score of 7.22 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend yield: 0.45%** ($3.64 per share, trailing). Regeneron Pharmaceuticals Inc. yields 0.45%, a modest yield more typical of a growth-oriented payer.
- **Payout ratio: 8%** (10% of free cash flow). 8% of earnings goes out as dividends, leaving room to keep raising it.
- **Consecutive years of increases: 1**. 1 straight year of increases.

## Analyst view
- **Analyst consensus: buy** (27 analysts). 27 analysts cover Regeneron Pharmaceuticals Inc.; the consensus is buy, with an average price target of $840.43 (+2% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 46.5%** (YTD 7.5%, 3-mo 30.3%). The shares are up 46.5% over twelve months including dividends.
- **From 52-week high: -3.7%** (53.0% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 60**. An RSI of 60 is neutral.
- **Beta (1 yr): 0.47** (volatility 34%). Beta of 0.47 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=REGN · Page: https://foliofundamentals.com/stocks/regn

Not investment advice.